Drug Safety Update is essential reading for all healthcare professionals, bringing you the very latest information and advice to support the safer use of medicines.
Drug safety advice
We previously advised that the contraindications for dabigatran had been clarified to include a range of clinical conditions where the patient is at significant risk of major bleeding, as well as in combination with other anticoagulant agents. Because similar risks are associated with the other new oral anticoagulants (apixaban and rivaroxaban), these contraindications have been applied across all three new oral anticoagulants for all indications and doses
Yellow Card Scheme update
For the first time, patients and the public will start to see information in Patient Information Leaflets about how to report suspected side effects via the Yellow Card Scheme